OBJECTIVE: Psoriatic arthritis (PsA) is associated with metabolic and cardiovascular disease. Studies have suggested that treatment with apremilast is associated with weight loss and other cardio-metabolic benefits. This study aimed to examine the effects of apremilast on body weight, body composition and cardiovascular risk factors in PsA patients. METHODS: This longitudinal, non-randomized, multicenter trial included adults with active PsA initiating apremilast (30 mg twice daily after a step-up regime). Patients were followed for 12 months, measurements were done at baseline and repeated at 26 and 52 weeks. Body composition, the primary outcome, was assessed using Dual Energy X-ray Absorptiometry (DEXA). Secondary outcomes included disease activity (DAS28-CRP), blood pressure, lipids, intima media thickness and glucose. Statistical analysis involved mixed models adjusted for relevant covariates. RESULTS: 44 patients were included, with mean age 56 years (±SD, 11 years) and median BMI of 28 kg/m